Adjunctive Measures and New Therapies to Optimize Early Return of Erectile Function

  • Nizar Boudiab
  • Usama Khater
  • Shirin Razdan
  • Sanjay Razdan


Even after the advent of nerve-sparing procedure a significant percent of patients still develop erectile dysfunction after radical prostatectomy [1]. Modifications in the surgical technique of robotic radical prostatectomy have aimed not only to spare the cavernous nerve but also to minimize any potential harm done from manipulation, traction, or thermal injury of the nerves in addition to sparing the microcirculation surrounding the prostate. The adjunctive measures to optimize early return of erectile function can be subdivided into intraoperative measures designed to optimize nerve preservation and minimize injury to the neurovascular structures surrounding the prostate, and postoperative penile rehabilitation to facilitate early return of erectile function.


Prostatectomy Robotic Optimizing Erectile function Outcome Measures Amniotic membrane 

Supplementary material

Video 9.1

Nerve preservation judicious use of thermal energy with dHam wrap (MP4 199313 kb)

Video 9.2

Optimizing erectile function with accessory pudendal artery preservation and judicious use of thermal energy (MP4 75084 kb)

Video 9.3

First in the world use of amniotic membrane in robotic prostatectomy for early return of erections (MP4 116775 kb)


  1. 1.
    Dubbelman D, Dohle R, Schroder H. Sexual function before and after radical retropubic prostatectomy: a systemic review of prognostic indicators for successful outcome. Eur Urol. 2006;50:711–8.CrossRefPubMedGoogle Scholar
  2. 2.
    Mulhall J. Defining and reporting erectile function outcomes after radical prostatectomy: challenges and miscoceptions. J Urol. 2009;181:462–71.CrossRefPubMedGoogle Scholar
  3. 3.
    Dahm P, Stoffs T, Canfield SE. Recovery of erectile function after robotic prostatectomy:evidence based outcomes. Urol Clin N Am. 2011;38(24):6.Google Scholar
  4. 4.
    Fairbain NG, Redmond RW. The clinical application of human amnion in plastic surgery. J Plast Reconstr Aesthet Surg. 2014;67(5):665–75.Google Scholar
  5. 5.
    Fesli A, Yilmaz N, Comelekoglu U, Tasdelen B. Enhancement of nerve healing with the combined use of amniotic membrane and granulocyte colony stimulation factor. J Plast Reconstr Aesthet Surg. 2014;67(5):837–43.CrossRefPubMedGoogle Scholar
  6. 6.
    Kim N, Verdi Y, Padma-Nathan H, Daley J, Goldstein I, Saenz de Tejada I. Oxygen tension regulates the nitric oxide pathway. Physiologic role in penile erection. J Clin Invest. 1993;91:437–42.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Klein L, Miller M, Buttyan R, et al. Apoptosis in the rat penis after penile denervation. J Urol. 1997;158:626–30.CrossRefPubMedGoogle Scholar
  8. 8.
    Lue T, Tanagho E. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829–36.Google Scholar
  9. 9.
    Mulhall J, Slovick R, Hotaling J, et al. Erectile dysfunction after radical prostatectomy: hemodynamic profiles and their correlation with recovery of erectile function. J Urol. 2002;167:1371–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Montorsi F, Guazzoni G, Strambi LF, et al. Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: results of a prospective, randomized trial. J Urol. 1997;158:1408–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Nandipati K, Raina R, Agarwal A, et al. Early combination therapy: intracavernosal injections and sildenafil following radical prostatectomy increases sexual activity and the return of natural erections. Int J Impot Res. 2006;18:446–51.CrossRefPubMedGoogle Scholar
  12. 12.
    Bannowsky A, Schulze H, van der Horst C, et al. Recovery of erectile function after nerve-sparing radical prostatectomy: improvement with nightly low-dose sildenafil. BJU Int. 2008;101:1279–83.CrossRefPubMedGoogle Scholar
  13. 13.
    Mulhall J, Land S, Parker M, et al. The use of an erectogenic pharmacotherapy regimen following radical prostatectomy improves recovery of spontaneous erectile function. J Sex Med. 2005;2:532–40. discussion 540–2.CrossRefPubMedGoogle Scholar
  14. 14.
    Padma-Nathan H, McCullough AR, Levine LA, Lipshultz LI, Siegel R, et al. Randomized, double-blind, placebo-controlled study of postoperative nightly sildenafil citrate for the prevention of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. Int J Impot Res. 2008;20:479–86.CrossRefPubMedGoogle Scholar
  15. 15.
    Mulhall JP, Burnett AL, Wang R, McVary KT, Moul JW, et al. A phase 3, placebo controlled study of the safety and efficacy of avanafil for the treatment of erectile dysfunction after nerve sparing radical prostatectomy. J Urol. 2013;189:2229–36.CrossRefGoogle Scholar
  16. 16.
    Teloken P, Mesquita G, Montorsi F, Mulhall J. Post-radical prostatectomy pharmacological penile rehabilitation: practice patterns among the international society for sexual medicine practitioners. J Sex Med. 2009;6(7):2032–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Mulhall JP, Bella AJ, Briganti A, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. J Sex Med. 2010;7(4 Pt 2):1687–98.CrossRefPubMedGoogle Scholar
  18. 18.
    Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol. 2004;171(2 Pt 1):771–4.CrossRefPubMedGoogle Scholar
  19. 19.
    Köhler TS, Pedro R, Hendlin K, Utz W, Ugarte R, Reddy P, et al. A pilot study on the early use of the vacuum erection device after radical retropubic prostatectomy. BJU Int. 2007;100(4):858–62.CrossRefPubMedGoogle Scholar
  20. 20.
    Raina R, Agarwal A, Ausmundson S, Lakin M, Nandipati KC, Montague DK, et al. Early use of vacuum constriction device following radical prostatectomy facilitates early sexual activity and potentially earlier return of erectile function. Int J Impot Res. 2006;18(1):77–81.CrossRefPubMedGoogle Scholar
  21. 21.
    Chung E, Brock G. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors. J Sex Med. 2013;10 Suppl 1:102–11.CrossRefPubMedGoogle Scholar
  22. 22.
    Salonia A, Burnett AL, Graefen M, Hatzimouratidis K, Montorsi F, Mulhall JP, et al. Prevention and management of postprostatectomy sexual dysfunctions. Part 1: choosing the right patient at the right time for the right surgery. Eur Urol. 2012;62(2):261–72.CrossRefPubMedGoogle Scholar
  23. 23.
    Chung E, Brock GB. Emerging and novel therapeutic approaches in the treatment of male erectile dysfunction. Curr Urol Rep. 2011;12(6):432–43.CrossRefPubMedGoogle Scholar
  24. 24.
    García-Cardoso J, Vela R, Mahillo E, Mateos-Cáceres PJ, Modrego J, Macaya C, et al. Increased cyclic guanosine monophosphate production and endothelial nitric oxide synthase level in mononuclear cells from sildenafil citrate-treated patients with erectile dysfunction. Int J Impot Res. 2010;22(1):68–76.CrossRefPubMedGoogle Scholar
  25. 25.
    Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, et al. Effect of nightly versus on-demand vardenafil on recovery of erectile function in men following bilateral nerve-sparing radical prostatectomy. Eur Urol. 2008;54:924–31.CrossRefPubMedGoogle Scholar
  26. 26.
    Montorsi F, Brock G, Stolzenburg JU, Mulhall J, Moncada I, et al. Effects of tadalafil treatment on erectile function recovery following bilateral nerve-sparing radical prostatectomy: a randomised placebo-controlled study (REACTT). Eur Urol. 2014;65:587–96.CrossRefPubMedGoogle Scholar
  27. 27.
    Natali A, Masieri L, Lanciotti M, Giancane S, Vignolini G, Carini M, et al. A comparison of different oral therapies versus no treatment for erectile dysfunction in 196 radical nerve-sparing radical prostatectomy patients. Int J Impot Res. 2015;27(1):1–5.CrossRefPubMedGoogle Scholar
  28. 28.
    Segal R, Burnett AL. Avanafil for the treatment of erectile dysfunction. Drugs Today. 2012;48(1):7–15.CrossRefPubMedGoogle Scholar
  29. 29.
    Paick JS, Kim JJ, Kim SC, et al. Efficacy and safety of mirodenafil in men taking antihypertensive medications. J Sex Med. 2010;7(9):3143–52.CrossRefPubMedGoogle Scholar
  30. 30.
    Toque HA, Teixeira CE, Lorenzetti R, Okuyama CE, Antunes E, De Nucci G. Pharmacological characterization of a novel phosphodiesterase type 5 (PDE5) inhibitor lodenafil carbonate on human and rabbit corpus cavernosum. Eur J Pharmacol. 2008;591(1–3):189–95.CrossRefPubMedGoogle Scholar
  31. 31.
    Alba F, Wang R. Current status of penile rehabilitation after radical prostatectomy. J Urol. 2010;16:93–101.Google Scholar
  32. 32.
    McCullough AR, Hellstrom WG, Wang R, Lepor H, Wagner KR, Engel JD. Recovery of erectile function after nerve sparing radical prostatectomy and penile rehabilitation with nightly intraurethral alprostadil versus sildenafil citrate. J Urol. 2010;183:2451–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Albersen M, Shindel AW, Lue TF. Sexual dysfunction in the older man. Rev Clin Gerontol. 2009;19(4):237–48.CrossRefGoogle Scholar
  34. 34.
    Raina R, Pahlajani G, Agarwal A, Zippe CD. The early use of transurethral alprostadil after radical prostatectomy potentially facilitates an earlier return of erectile function and successful sexual activity. BJU Int. 2007;100(6):1317–21.CrossRefPubMedGoogle Scholar
  35. 35.
    Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005;293:2648–53.CrossRefPubMedGoogle Scholar
  36. 36.
    Claro JA, de Aboim JE, Maríngolo M, Andrade E, Aguiar W, Nogueira M, et al. Intracavernous injection in the treatment of erectile dysfunction after radical prostatectomy: an observational study. Sao Paulo Med J. 2001;119:135–7.CrossRefGoogle Scholar
  37. 37.
    Gontero P, Fontana F, Bagnasacco A, Panella M, Kocjancic E, Pretti G, et al. Is there an optimal time for intracavernous prostaglandin E1 rehabilitation following nonnerve sparing radical prostatectomy? Results from a hemodynamic prospective study. J Urol. 2003;169(6):2166–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Mulhall JP, Parker M, Waters BW, Flanigan R. The timing of penile rehabilitation after bilateral nerve-sparing radical prostatectomy affects the recovery of erectile function. BJU Int. 2010;105:37–41.CrossRefPubMedGoogle Scholar
  39. 39.
    Yiou R, Tow BZ, Parisot J, et al. Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year? J Sex Med. 2015;3:42–8.CrossRefGoogle Scholar
  40. 40.
    Lewis R, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15:78–82.CrossRefPubMedGoogle Scholar
  41. 41.
    Brison D, Seftel A, Sadeghi-Nejad H. The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med. 2013;10:1124–35.CrossRefGoogle Scholar
  42. 42.
    Lin H, Yang W, Zhang J, Dai Y, Wang R. Penile rehabilitation with a vacuum erectile device in an animal model is related to an antihypoxic mechanism: blood gas evidence. Asian J Androl. 2013;15:387–90.CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Yuan J, Hoang A, Romero C, Lin H, Dai Y, Wang R. Vacuum therapy in erectile dysfunction—science and clinical evidence. Int J Impot Res. 2010;22:211–9.CrossRefPubMedGoogle Scholar
  44. 44.
    Yuan J, Lin H, Li P, Zhang R, Luo A, Berardinelli F, et al. Molecular mechanisms of vacuum therapy in penile rehabilitation: a novel animal study. Eur Urol. 2010;58:773–80.CrossRefPubMedGoogle Scholar
  45. 45.
    Yuan J, Westney O, Wang R. Design and application of a new rat-specific vacuum erectile device for penile rehabilitation research. J Sex Med. 2009;6:3247–53.CrossRefPubMedGoogle Scholar
  46. 46.
    Monga M, Utz W, Reddy P, Kohler T, Hendlin K, et al. Early use of the vacuum constriction device following radical retropubic prostatectomy: a randomized clinical trial south central section of the AUA 85th annual meeting; 2006. p. 98.Google Scholar
  47. 47.
    Bosshardt RJ, Farwerk R, Sikora R, Sohn M, Jakse G. Objective measurement of the effectiveness, therapeutic success and dynamic mechanisms of the vacuum device. Br J Urol. 1995;75:786–91.CrossRefPubMedGoogle Scholar
  48. 48.
    Gontero P, Fontana F, Zitella A, Montorsi F, Frea B. A prospective evaluation of efficacy and compliance with a multistep treatment approach for erectile dysfunction in patients after non-nerve sparing radical prostatectomy. BJU Int. 2005;95:359–65.CrossRefPubMedGoogle Scholar
  49. 49.
    Raina R, Agarwal A, Allamaneni SS, Lakin MM, Zippe CD. Sildenafil citrate and vacuum constriction device combination enhances sexual satisfaction in erectile dysfunction after radical prostatectomy. Urology. 2005;65:360–4.CrossRefPubMedGoogle Scholar
  50. 50.
    Raina R, Pahlajani G, Agarwal A, Jones S, Zippe C. Long-term potency after early use of a vacuum erection device following radical prostatectomy. BJU Int. 2010;106:1719–22.CrossRefPubMedGoogle Scholar
  51. 51.
    Engel JD. Effect on sexual function of a vacuum erection device post-prostatectomy. Can J Urol. 2011;18:5721–5.PubMedGoogle Scholar
  52. 52.
    Basal S, Wambi C, Acikel C, Gupta M, Badani K. Optimal strategy for penile rehabilitation after robot-assisted radical prostatectomy based on preoperative erectile function. BJU Int. 2013;111:658–65.CrossRefPubMedGoogle Scholar
  53. 53.
    Montorsi F, Adaikan G, Becher E, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010;7(11):3572–88.CrossRefGoogle Scholar
  54. 54.
    Stein M, Lin H. New advances in erectile technology. Ther Adv Urol. 2014;6(1):15–24.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Lim P. Recent advances and research updates. 2003. ISSN-0972-4689.Google Scholar
  56. 56.
    Le B, Colombo A, Mustoe T, McVary K. Evaluation of a Ni-Ti shape memory alloy for use in a novel penile prosthesis. J Urol. 2013;189(Suppl):502.CrossRefGoogle Scholar
  57. 57.
    Swords K, Martinez D, Lockhart J, Carrion R. A preliminary report on the usage of an intracorporeal antibiotic cast with synthetic high purity CaSO4 for the treatment of infected penile implant. J Sex Med. 2013;10:1162–9.CrossRefPubMedGoogle Scholar
  58. 58.
    Yap RL, Mcvary KT. Topical agents and erectile dysfunction: is there a place? Curr Urol Rep. 2002;3:471–6.CrossRefPubMedGoogle Scholar
  59. 59.
    Montorsi F, Salonia A, Zanoni M, Pompa P, Cestari A, Guazzoni G, et al. Current status of local penile therapy. Int J Impot Res. 2002;14(1 suppl):S70–81.CrossRefPubMedGoogle Scholar
  60. 60.
    Friedman AJ, Han G, Navati MS, Chacko M, Gunther L, Alfieri A, et al. Sustained release nitric oxide releasing nanoparticles: characterization of a novel delivery platform based on nitrite containing hydrogel/glass composites. Nitric Oxide. 2008;19:12–20.CrossRefPubMedGoogle Scholar
  61. 61.
    Gupta R, Kumar A. Bioactive materials for biomedical applications using sol-gel technology. Biomed Mater. 2008;3:034005.CrossRefPubMedGoogle Scholar
  62. 62.
    Khan I, Dantsker D, Samuni U, Friedman AJ, Bonaventura C, Manjula B, et al. Beta 93 modified hemoglobin: kinetic and conformational consequences. Biochemistry. 2001;40:7581–92.CrossRefPubMedGoogle Scholar
  63. 63.
    Khan I, Shannon CF, Dantsker D, Friedman AJ, Perez-Gonzalez-de-Apodaca J, Friedman JM. Sol-gel trapping of functional intermediates of hemoglobin: geminate and bimolecular recombination studies. Biochemistry. 2000;39:16099–109.CrossRefPubMedGoogle Scholar
  64. 64.
    Viitala R, Jokinen M, Rosenholm JB. Mechanistic studies on release of large and small molecules from biodegradable SiO2. Int J Pharm. 2007;336:382–90.CrossRefPubMedGoogle Scholar
  65. 65.
    Han G, Tar M, Kuppam D, Friedman A, Melman A, Friedman J, et al. Nanoparticles as a novel delivery vehicle for therapeutics targeting erectile dysfunction. J Sex Med. 2010;7:224–33.CrossRefPubMedGoogle Scholar
  66. 66.
    Davies KP, Tar M, Rougeot C, Melman A. Sialorphin (the mature peptide product of Vcsa1) relaxes corporal smooth muscle tissue and increases erectile function in the ageing rat. BJU Int. 2007;99:431–5.CrossRefPubMedGoogle Scholar
  67. 67.
    Seftel AD. Phosphodiesterase type 5 inhibitor differentiation based on selectivity, pharmacokinetic, and efficacy profiles. Clin Cardiol. 2004;27(4 suppl 1):114–9.Google Scholar
  68. 68.
    Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering U, Bulitta J, Schreiner P, et al. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther. 2002;71:21–9.CrossRefPubMedGoogle Scholar
  69. 69.
    Young S, Dyson M. The effect of therapeutic ultrasound on angiogenesis. Ultrasound Med Biol. 1990;16:261–9.CrossRefPubMedGoogle Scholar
  70. 70.
    Qiu X, Lin G, Xin Z, Ferretti L, Zhang H, Lue T, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med. 2013;10:738–46.CrossRefPubMedGoogle Scholar
  71. 71.
    Wang C, Huang H, Pai C. Shock wave-enhanced neovascularization at the tendon-bone junction: an experiment in dogs. J Foot Ankle Surg. 2002;41:16–22.CrossRefPubMedGoogle Scholar
  72. 72.
    Wang C, Wang F, Yang K, Weng L, Hsu C, Huang C, et al. Shock wave therapy induces neovascularization at the tendon-bone junction. A study in rabbits. J Orthop Res. 2003;21:984–9.CrossRefPubMedGoogle Scholar
  73. 73.
    Gutersohn A, Caspari G, Vopahl M, Erbel R. Upregulation of VEGF mRNA in HUVEC via shock waves. In: Proceedings of the international conference from genes to therapy in ischemic and heart muscle disease, Marburg, Germany, 9–10 Oct 1999.Google Scholar
  74. 74.
    Nishida T, Shimokawa H, Oi K, Tatewaki H, Uwatoku T, Abe T, et al. Extracorporeal cardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation. 2004;110:3055–61.CrossRefPubMedGoogle Scholar
  75. 75.
    Aicher A, Heeschen C, Sasaki K, Urbich C, Zeiher A, Dimmeler S. Low-energy shock wave for enhancing recruitment of endothelial progenitor cells: a new modality to increase efficacy of cell therapy in chronic hind limb ischemia. Circulation. 2006;114:2823–30.CrossRefPubMedGoogle Scholar
  76. 76.
    Vardi Y, Appel B, Jacob G, Massarwi O, Gruenwald I. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol. 2010;58:243–8.CrossRefPubMedGoogle Scholar
  77. 77.
    Vardi Y, Appel B, Kilchevsky A, Gruenwald I. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol. 2012;187:1769–75.CrossRefPubMedGoogle Scholar
  78. 78.
    Walz J, Burnett AL, Costello AJ, Eastham JA, Graefen M, Guillonneau B, et al. A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol. 2010;57:179–92.CrossRefPubMedGoogle Scholar
  79. 79.
    Rogers CG, Trock BP, Walsh PC. Preservation of accessory pudendal arteries during radical retropubic prostatectomy: surgical technique and results. Urology. 2004;64:148–51.CrossRefPubMedGoogle Scholar
  80. 80.
    Mulhall JP, Secin FP, Guillonneau B. Artery sparing radical prostatectomy – myth or reality? J Urol. 2008;179:827–31.CrossRefPubMedGoogle Scholar
  81. 81.
    Moreland RB. Is there a role of hypoxemia in penile fibrosis: a viewpoint presented to the Society for the Study of Impotence. Int J Impot Res. 1998;10:113–20.CrossRefPubMedGoogle Scholar
  82. 82.
    Nehra A, Hall SJ, Basile G, Bertero EB, Moreland R, Toselli P, et al. Systemic sclerosis and impotence: a clinicopathological correlation. J Urol. 1995;153:1140–6.CrossRefPubMedGoogle Scholar
  83. 83.
    Pelka R, Jaenicke C, Gruenwald J. Impulse magnetic-field therapy for erectile dysfunction: a double-blind, placebo-controlled study. Adv Ther. 2002;19:53–60.CrossRefPubMedGoogle Scholar
  84. 84.
    Shafik A, El-Sibai O, Shafik A. Magnetic stimulation of the cavernous nerve for the treatment of erectile dysfunction in humans. Int J Impot Res. 2000;12:137–41. discussion 141–132.CrossRefPubMedGoogle Scholar
  85. 85.
    Tajkarimi K, Burnett A. Viberect® device use by men with erectile dysfunction: safety, ease of use, tolerability, and satisfaction survey. J Sex Med. 2011;8:441.CrossRefGoogle Scholar
  86. 86.
    Fode M, Borre M, Ohl DA, Lichtbach J, Sønksen J. Penile vibratory stimulation in the recovery of urinary continence and erectile function after nerve-sparing radical prostatectomy: a randomized, controlled trial. BJU Int. 2014;114:111–7.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Yoo J, Lee I, Atala A. Cartilage rods as a potential material for penile reconstruction. J Urol. 1998;160:1164–8. discussion 1178.CrossRefPubMedGoogle Scholar
  88. 88.
    Yoo J, Park H, Lee I, Atala A. Autologous engineered cartilage rods for penile reconstruction. J Urol. 1999;162:1119–21.CrossRefPubMedGoogle Scholar
  89. 89.
    Kershen R, Yoo J, Moreland R, Krane R, Atala A. Reconstitution of human corpus cavernosum smooth muscle in vitro and in vivo. Tissue Eng. 2002;8:515–24.CrossRefPubMedGoogle Scholar
  90. 90.
    Chen K, Eberli D, Yoo J, Atala A. Bioengineered corporal tissue for structural and functional restoration of the penis. Proc Natl Acad Sci U S A. 2010;107:3346–50.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2016

Authors and Affiliations

  • Nizar Boudiab
    • 1
  • Usama Khater
    • 1
  • Shirin Razdan
    • 2
  • Sanjay Razdan
    • 1
  1. 1.International Robotic Prostatectomy InstituteUrology Center of Excellence at Jackson South HospitalMiamiUSA
  2. 2.University of Miami Miller School of MedicineMiamiUSA

Personalised recommendations